Levomepromazine (methotrimeprazine) and the last 48 hours

Title

Levomepromazine (methotrimeprazine) and the last 48 hours

Creator

O'Neill J; Fountain A

Publisher

Hospital Medicine

Date

1999

Subject

Humans; Terminal Care; Non-U.S. Gov't; Research Support; Terminally Ill/psychology; Psychotic Disorders/drug therapy; Antipsychotic Agents/pharmacology/therapeutic use; Methotrimeprazine/pharmacology/therapeutic use; Psychomotor Agitation/therapy

Description

Levomepromazine (previously known as methotrimeprazine) has a broad range of beneficial effects in the terminal phase of many illnesses, resulting from its combined antipsychotic, anxiolytic and sedative actions. Levomepromazine can safely be administered in a continuous subcutaneous infusion with most other commonly used drugs in palliative care.
1999

Rights

Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).

Type

Journal Article

Citation List Month

Backlog

Citation

O'Neill J; Fountain A, “Levomepromazine (methotrimeprazine) and the last 48 hours,” Pediatric Palliative Care Library, accessed August 7, 2022, https://pedpalascnetlibrary.omeka.net/items/show/11794.

Social Bookmarking